Effectiveness of treatment with nebulized colistin in patients with COPD
Bruguera Àvila, Núria (Universitat Autònoma de Barcelona. Departament de Medicina)
Marín, Alicia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Garcia-Olivé, Ignasi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Radua, Joaquim (Karolinska Institutet (Estocolm, Suècia). Department of Clinical Neuroscience)
Prat i Aymerich, Cristina (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
Gil, Montserrat (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Ruiz Manzano, J.. (Universitat Autònoma de Barcelona. Departament de Medicina)

Fecha:	2017
Resumen:	To analyze whether the introduction of nebulized colistin in patients with chronic obstructive pulmonary disease (COPD) and infection with Pseudomonas aeruginosa (PA) is associated with a decrease of the number and duration of severe exacerbations. Thirty six patients with COPD and infection with PA treated with nebulized colistin attending a day hospital during a 5-year (January 2010-December 2014) period were prospectively included. Repeated-measures t -tests were used to assess whether the introduction of colistin was associated with changes in the number of exacerbations or the length of the hospitalizations, comparing for each patient the year prior to the introduction of colistin with the year after. After the introduction of colistin, the number of admissions decreased from 2. 0 to 0. 9 per individual year (P =0. 0007), and hospitalizations were shorter (23. 3 vs 10. 9 days, P =0. 00005). These results persisted when patients with and without bronchiectasis or with and without persistence of Pseudomonas were separately analyzed. No pre-post differences were detected in the number of exacerbations not requiring admission. Nebulized colistin seems associated with a strong decrease in the number and duration of hospitalizations due to exacerbation in patients with COPD and infection with PA. Clinical trials with a larger number of patients are needed in order to confirm these results.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Bronchiectasis ; Colistin ; COPD ; Nebulized antibiotics
Publicado en:	International journal of COPD, Vol. 12 (october 2017) , p. 2909-2915, ISSN 1178-2005

DOI: 10.2147/COPD.S138428
PMID: 29042767

7 p, 280.3 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Artículos > Artículos de investigación
Artículos > Artículos publicados